EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of anaemia related to myelodysplastic syndromes with erythropoietin A trial in 32 patients



Treatment of anaemia related to myelodysplastic syndromes with erythropoietin A trial in 32 patients



Leukemia Research 27(Supplement 1): S100




(PDF 0-2 workdays service: $29.90)

Accession: 035980936

Download citation: RISBibTeXText



Related references

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model. British Journal of Haematology 99(2): 344-351, 1997

The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. British Journal of Haematology 77(3): 419-423, 1991

Recombinant human erythropoietin for the treatment of anaemia in the myelodysplastic syndromes. Leukemia Research 15(SUPPL): 22, 1991

Recombinant human erythropoietin for the treatment of anaemia in myelodysplastic syndromes: Metaanalytical study. Sangre (Saragossa) 39(6): 435-439, 1994

A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes. Leukemia Research. 20(8): 693-699, 1996

Current use of recombinant human erythropoietin in the management of symptomatic anaemia in patients with myelodysplastic syndromes. Sangre (Saragossa) 39(2): 105-110, 1994

High-dose recombinant human erythropoietin administered intravenously for the treatment of anaemia in myelodysplastic syndromes. Acta Haematologica 87 Suppl 1: 25-27, 1992

Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS). Sangre 39(2): 105-110, 1994

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet. Haematology, 2018

A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leukemia & Lymphoma 11(3-4): 221-228, 1993

Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. British Journal of Haematology 109(2): 367-375, 2000

Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment. Haematologica 95(2): 339-340, 2010

Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. Annals of Hematology 66(4): 175-180, 1993

A phase i ii trial of erythropoietin epoetin beta epo in patients with myelodysplastic syndromes mds. Leukemia Research 15(SUPPL): 13, 1991

Erythropoietin plus G-CSF in the treatment of anemia in myelodysplastic syndromes Results of a randomised trial with impact on quality of life and costs. Blood 98(11 Part 1): 848a, November 16, 2001